Technological asset

ISMORE: Intracranial device for rehabilitation of neurological damage



The incidence and prevalence of stroke in Europe is 1.1 and 6 million people, respectively, and is growing annually by 10%.

So far, there is no standardised rehabilitation therapy for completely paralysed patients after stroke (30%) who have no residual movement.

In certain cases, patients are subjected to passive physical therapy without any functional benefit and in very few cases the patient's spasticity and blood circulation are improved.

Potential Market

  • Neurotechnology: €8 trillion in 2016; €12 trillion in 2020; CAGR 12%
  • Wearable robots, exoskeletons: €36M in 2015; €2.1B in 2021
  • Neurorobots: €200M en 2018
  • Target global market of 7M people and 300,000 new patients each year
  • Without competitors offering therapy to completely paralysed patients

We offer

  • TRL 5
  • Technology protected by the patent families derived from WO2016076886 (EP granted) and WO2018096188
  • Collaborative development with first-level partners: A consortium including Berkeley University, Tubingen University and Donostia Hospital. With the participation of UPV/EHU, ULB, CITA and Biodonostia
  • Clinical trial in progress. Positive results on first patient
  • Advanced prototypes
  • Internationally renowned expert technical team

We are searching for

  • Investors
  • Developers
  • Partners
  • Networking



Registration No.

System for motor rehabilitation of a parectic limb in stroke patients


Paretic limb rehabilitation method and system